Contact

 

Pipeline

Vaxdyn´s core expertise lies in development of alternatives to antibiotics for treatment of infections produced by multi-drug resistant bacteria. Specifically, Vaxdyn’s first target is multi- and pan-resistant Acinetobacter baumannii. The company has advanced its lead compound VXD-001, a unique and universal preventive vaccine into the late preclinical phase. VXD-001 could target a global population at risk of contracting infections of 74 million people. For those not targeted by vaccination, Vaxdyn is developing VXD-003, a treatment based on monoclonal antibodies raised against universal epitopes of the bacteria, currently in early preclinical phase. Vaxdyn is also developing a prophylactic vaccine against Pseudomonas aeruginosa based on recombinant protein antigens (VXD-002). VXD-002 is currently in the discovery phase of development. With the confirmed interest of multinational pharmaceutical companies looking for new products against antibiotic-resistant bacteria, the company is seeking to close a Series A capitalization round to complete clinical phase I and licensing out VXD-001.

VXD-001

The most advanced vaccine candidate against multi-drug resistant Acinetobacter baumannii. 
The VXD-001 vaccine candidate is based on inactivated whole cells of a specific strain of Acinetobacter baumannii, which has been genetically engineered to completely eliminate the endotoxin component of the cell membrane (lipopolysaccharide or LPS). The product has been protected by the PCT international patent application PCT/EP2015/059870 (priority date 05 May 2014).

Vaxdyn´s scientists have been able to completely remove the LPS from Acinetobacter’s cell wall while the bacteria is still viable and has been used to develop the vaccine´s manufacturing process. This is the third time in the history of microbiology that a Gram-negative bacterial species has been completely depleted of LPS and has maintained viability. There are 2 important strategic properties of the vaccine linked to this fact:

  1. First, by eliminating the endotoxin, a vaccine based on whole cells can be used. By using whole cells, the vaccinated individual develops immunity against many bacterial antigens. This strategy, which has been used successfully with viruses and it is the basis of the majority of vaccines for prevention of viral infections, cannot be applied generally to bacterial infections in humans, since the presence of the endotoxin makes vaccination with whole cells highly toxic. This problem has been solved in VXD-001.

  2. And second, since LPS is one of the most variable immunogenic components of the bacterial cell wall, its elimination focuses the host to raise immunity on several more conserved immunodominant epitopes. VXD-001 is a universal vaccine, which raises protective immunity against Acinetobacter strains from all international clones and all tested clinical isolates from different regions of the world.

These properties have been extensively tested in the preclinical assays carried out in validated murine models of sepsis and pneumonia. VXD-001 is a much stronger vaccine candidate against Acinetobacter baumannii than any other candidate in preclinical development.

VXD-002

A prophylactic vaccine against Pseudomonas aeruginosa.
VXD-002 is a prophylactic vaccine based on recombinant surface antigens from P. aeruginosa. Vaxdyn’s scientists have used genomic and quantitative proteomic techniques to identify highly conserved surface proteins from P. aeruginosa that can serve as antigens for the development of a vaccine. The vaccine candidates identified by Vaxdyn are currently being evaluated in preclinical models of infection in order to characterize their efficacy.

VXD-003

Therapeutic monoclonal antibodies for treating infections caused by multidrug resistant Acinetobacter baumannii.New treatments are needed for the increasing number of infections caused by strains of Acinetobacter baumannii that is not sensitive to conventional antibiotics. In order to respond to this medical need, Vaxdyn is developing a novel treatment approach based on therapeutic monoclonal antibodies that have activity against A. baumannii. Vaxdyn’s scientists have developed numerous antibody candidates that are specific for highly conserved surface epitopes of A. baumannii. These antibodies are currently being characterized in preclinical models of infection in order to evaluate their efficacy.